Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, announced today the close of a $33 million oversubscribed Series A financing. Cerberus Ventures led the round, with participation from new investors Mansueto Investments, Woori Venture Partners and Apollo Labs. Founding investors BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures and Cerity Partners Ventures also participated. Syntis has also secured up to $5 million in non-dilutive funding from the National Institutes of Health (NIH) through two Fast-Track Small Business Innovation Research (SBIR) awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supporting the advancement of its SYNT™ (SYNthetic Tissue-lining) platform.
Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small Intestine
Syntis Bio, Inc. (Syntis) today announced its launch as a clinical-stage biopharmaceutical company with a mission to develop oral therapies that provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. By harnessing the small intestine’s unique biology as the nexus for metabolic control, digestion and drug absorption, the company is rapidly advancing a portfolio of programs addressing metabolic diseases ranging from obesity to rare pediatric indications homocystinuria (HCU) and maple syrup urine disease (MSUD).
